Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for Momenta Pharmaceuticals, Inc
11.47
+0.12 (1.10%)
Oct 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.11 - 11.73
52 week 9.85 - 19.90
Open 11.34
Vol / Avg. 632,304.00/326,517.00
Mkt cap 598.90M
P/E     -
Div/yield     -
EPS -2.13
Shares 52.81M
Beta 2.01
Inst. own 84%
Nov 3, 2014
Q3 2014 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 14, 2014
Momenta Pharmaceuticals Inc at Canaccord Genuity Growth Conference
Jul 31, 2014
Q2 2014 Momenta Pharmaceuticals Inc Earnings Call - Webcast
Jul 31, 2014
Q2 2014 Momenta Pharmaceuticals, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -238.87% -305.68%
Operating margin -240.71% -309.01%
EBITD margin - -285.89%
Return on average assets -37.58% -29.97%
Return on average equity -44.35% -34.40%
Employees 269 -
CDP Score - -

Address

675 West Kendall Street
CAMBRIDGE, MA 02142
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). This results in a diversified product pipeline of complex generic, follow-on biologic (FOB) and novel drugs. The Company�s complex generic programs target marketed products, which were originally approved by the United States Food and Drug Administration (FDA) as New Drug Applications (NDAs). Its M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). During the year ended December 31, 2011, it acquired the assets of Virdante. On February 13, 2012 it entered into a global collaboration (Baxter Agreement) with Baxter International Inc.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 62
Bio & Compensation  - Reuters
Michael Franken M.D. President - Biosimilars Business, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Bruce A. Leicher Esq. Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
John E. Bishop Ph.D. Senior Vice President - Pharmaceutical Sciences
Age: 52
Bio & Compensation  - Reuters
James M. Roach M.D. Senior Vice President - Development, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 60
Bio & Compensation  - Reuters
Bruce L. Downey Independent Director
Age: 67
Bio & Compensation  - Reuters